The Different Immunoregulatory Functions on Dendritic Cells between Mesenchymal Stem Cells Derived from Bone Marrow of Patients with Low-Risk or High-Risk Myelodysplastic Syndromes

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Wang, Zhenling ^a   Tang, Xiaoqiong ^b   Xu, Wen ^a   Cao, Zeng ^c   Sun, Li ^d   Li, Weiming ^d   Li, Qiubai ^d   Zou, Ping ^d   Zhao, Zhigang ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b CHONGQING MEDICAL UNIVERSITY   (China)

^c INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

^d HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ARTICLE; CELL DIFFERENTIATION; CELL MATURATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; ENDOCYTOSIS; HUMAN; HUMAN CELL; IMMUNOREGULATION; LYMPHOCYTE PROLIFERATION; MESENCHYMAL STEM CELL; MONOCYTE; MYELODYSPLASTIC SYNDROME; T LYMPHOCYTE;

ADULT; AGED; BONE MARROW CELLS; CELL COMMUNICATION; CELL DIFFERENTIATION; CELL PROLIFERATION; COCULTURE TECHNIQUES; DENDRITIC CELLS; ENDOCYTOSIS; HUMANS; IMMUNOMODULATION; INTERLEUKIN-12; LYMPHOCYTE ACTIVATION; MESENCHYMAL STROMAL CELLS; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTES; TRANSFORMING GROWTH FACTOR BETA;

EID: 84874639295     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0057470     Document Type: Article

References (35)

1. Heaney ML, Golde DW, (1999) Myelodysplasia.New England Journal of Medicine. 340: 1649-60.
2. Smyth MJ, Dunn GP, Schreiber RD, (2006) Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Advances in Immunology 90: 1-50.
3. Alfinito F, Sica M, Luciano L, Pepa RD, Palladino C, et al. (2010) Immune dysregulation and dyserythropoiesis in the myelodysplastic syndromes. Br J Haematol 48: 90-98.
4. Chan AC, Neeson P, Leeansyah E, Tainton K, Quach H, et al. (2010) Testing the NKT cell hypothesis in lenalidomide-treated myelodysplastic syndrome patients. Leukemia 24: 592-600.
5. Epperson DE, Nakamura R, Saunthararajah Y, Melenhorst J, Barrett AJ, (2001) Oligoclonal T cell expansion in myelodysplastic syndrome: evidence for an autoimmune process.Leuk Res. 25: 1075-1083.
6. Maciejewski JP, (2007) Immune-mediated bone marrow failure syndromes of progenitor and stem cells: molecular analysis of cytotoxic T cell clones. Folia Histochemica et Cytochemica 45: 5-14.
7. Kordasti SY, Ingram W, Hayden J, Darling D, Barber L, et al. (2007) CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS). Blood 110: 847-50.
8. Tlsty TD, Coussens LM, (2006) Tumor stroma and regulation of cancer development. Annual Review of Patholology 1: 119-50.
9. Kordasti SY, Afzali B, Lim Z, Ingram W, Hayden J, et al. (2009) IL-17-producing CD4(+) T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome. British Journal of Haematology 145: 64-72.
10. Aggarwal S, van de Loosdrecht AA, Alhan C, Ossenkoppele GJ, Westers TM, et al. (2011) Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy. Br J Haematol 153: 568-81.
11. Mellman I, Steinman RM, (2001) Dendritic cells: specialized and regulated antigen processing machines. Cell 106: 255-8.
12. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, et al. (2000) Immunobiology of dendritic cells. Annu Rev Immunol 18: 767-11.
13. Aggarwal S, Pittenger MF, (2005) Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105: 1815-22.
14. Zhang W, Ge W, Li CH, You SG, Liao LM, et al. (2004) Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells. Stem Cell and Development 13: 263-71.
15. Jiang XX, Zhang Y, Liu B, Zhang SX, Wu Y, et al. (2005) Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 105: 4120-26.
16. Zhao ZG, Li WM, Chen ZC, You Y, Zou P, (2008) Immunosuppressive properties of mesenchymal stem cells derived from bone marrow of patient with hematological malignant diseases. Leukemia & Lymphoma 9: 2187-95.
17. Guo H, Fang B, Liao L, Zhao Z, Liu J, et al. (2003) Hemangioblastic characteristics of fetal bone marrow-derived Flk1+CD31-CD34-cells. Exp Hematol 31: 650-58.
18. Gorelik L, Flavell RA, (2002) Transforming growth factor-beta in T-cell biology. Nat Rev Immunol 2: 46-53.
19. Zhao ZG, Xu W, Li F, Li WM, Li QB, et al. (2012) Functional characteristics of mesenchymal stem cells derived from bone marrow of patients with myelodysplastic syndromes. Cancer Letters. 317: 136-43.
20. Spaggiari GM, Abdelrazik H, Becchetti F, Moretta L, (2009) MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2. Blood 113: 6576-83.
21. Djouad F, Charbonnier LM, Bouffic C, Plence PL, Bony C, et al. (2007) Mesenchymal Stem Cells Inhibit the Differentiation of Dendritic Cells Through an Interleukin-6-Dependent Mechanism. Stem Cells 25: 2025-32.
22. Tauro S, Hepburn MD, Peddie CM, Bowen DT, Pippard MJ, (2002) Functional disturbance of marrow stromal microenvironment in the myelodysplastic syndromes. Leukemia 16: 785-90.
23. Epperson DE, Nakamura R, Saunthararajah Y, Melenhorst J, Barrett AJ, (2001) Oligoclonal T cell expansion in myelodysplastic syndrome: evidence for an autoimmune process. Leuk Res 25: 1075-83.
24. Wlodarski MW, O'Keefe C, Howe EC, Risitano AM, Rodriguez A, et al. (2005) Pathologic clonal cytotoxic T-cell responses: nonrandom nature of the T-cell-receptor restriction in large granular lymphocyte leukemia. Blood 106: 2769-80.
25. Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC, (2003) Suppression of allogeneic T-cell proliferation by human marrow stromal cells:Implications in transplantation, Transplantation. 75: 389-97.
26. Krampera M, Glennie S, Dyson J, Scott D, Laylor R, et al. (2003) Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 101: 3722-29.
27. Spaggiari GM, Capobianco A, Abdelrazik H, Becchetti F, Mingari MC, et al. (2008) Mesenchymal stem cells inhibit natural killer cell proliferation, cytotoxicity and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood 111: 1327-33.
28. Corcione A, Benvenuto F, Ferretti E, Giunti D, Cappiello V, et al. (2006) Human mesenchymal stem cells modulate B-cell functions. Blood 107: 367-72.
29. Mellman I, Steinman RM, (2001) Dendritic cells: specialized and regulated antigen processing machines. Cell 106: 255-58.
30. Banchereau J, Steinman RM, (1998) Dendritic cells and the control of immunity. Nature 392: 245-52.
31. Shi Y, Massague J, (2003) Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell 113: 685-700.
32. Chen W, Wahl SM, (2002) TGF-beta: receptors, signaling pathways and autoimmunity. Curr Dir Autoimmun 5: 62-91.
33. Mantel PY, Schmidt-Weber CB, (2011) Transforming growth factor-beta: recent advances on its role in immune tolerance. Methods Mol Biol 677: 303-38.
34. Buck MB, Knabbe C, (2006) TGF-beta signaling in breast cancer.Ann N Y Acad Sci. 1089: 119-26.
35. Zhao ZG, Li WM, Chen ZC, Zou P, (2008) Immunosuppressive properties of mesenchymal stem cells derived from bone marrow of patients with chronic myeloid leukemia. Immunological Investigations 37: 726-39.